{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T12:28:30Z","timestamp":1781353710538,"version":"3.54.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/fpc.0b013e328351f3e9","type":"journal-article","created":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T09:18:45Z","timestamp":1330593525000},"page":"381-388","source":"Crossref","is-referenced-by-count":16,"title":["Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression"],"prefix":"10.1097","volume":"22","author":[{"given":"Roc\u00edo","family":"Benito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lumbreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Ab\u00e1igar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana E.","family":"Rodr\u00edguez-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Consuelo","family":"Ca\u00f1izo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Maria Hern\u00e1ndez","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210214","first-page":"63","article-title":"FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.","volume":"1","author":"Jagani","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"R2-7-20210214","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcrabl gene of the Philadelphia chromosome.","volume":"4944","author":"Daley","year":"1990","journal-title":"Science"},{"key":"R3-7-20210214","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis.","volume":"11","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"R4-7-20210214","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.181.1.307","article-title":"Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.","volume":"1","author":"Sawyers","year":"1995","journal-title":"J Exp Med"},{"key":"R5-7-20210214","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCRABL requires activation of a PI-3kAkt-dependent pathway.","volume":"20","author":"Skorski","year":"1997","journal-title":"EMBO J"},{"key":"R6-7-20210214","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1128\/MCB.11.2.1107","article-title":"Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants.","volume":"2","author":"Varticovski","year":"1991","journal-title":"Mol Cell Biol"},{"key":"R7-7-20210214","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BcrAbl.","volume":"3","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"key":"R8-7-20210214","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.","volume":"7","author":"Reuther","year":"1998","journal-title":"Genes Dev"},{"key":"R9-7-20210214","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAKSTAT, RafMEKERK, PI3KAkt and BCR-ABL in cell cycle progression and leukemogenesis.","volume":"2","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"R10-7-20210214","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"14","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-7-20210214","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia 1.","volume":"9","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"R12-7-20210214","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study 5.","volume":"10","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"R13-7-20210214","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"5","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"R14-7-20210214","first-page":"675","article-title":"Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers 1.","volume":"5","author":"Gambacorti-Passerini","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R15-7-20210214","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2004-12-4938","article-title":"Global approach to the diagnosis of leukemia using gene expression profiling.","volume":"4","author":"Haferlach","year":"2005","journal-title":"Blood"},{"key":"R16-7-20210214","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.beha.2009.04.002","article-title":"The impact of gene profiling in chronic myeloid leukaemia 1.","volume":"2","author":"Yong","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"R17-7-20210214","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/10428190801896194","article-title":"Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia 1.","volume":"4","author":"Schmidt","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R18-7-20210214","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures 4.","volume":"4","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"key":"R19-7-20210214","first-page":"254","article-title":"A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia 1.","volume":"2","author":"De","year":"2010","journal-title":"Leuk Res"},{"key":"R20-7-20210214","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","article-title":"Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.","volume":"8","author":"Frank","year":"2006","journal-title":"Leukemia"},{"key":"R21-7-20210214","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1349-7006.2002.tb01328.x","article-title":"Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis 1.","volume":"8","author":"Kaneta","year":"2002","journal-title":"Jpn J Cancer Res"},{"key":"R24-7-20210214","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","article-title":"Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.","volume":"6","author":"Villuendas","year":"2006","journal-title":"Leukemia"},{"key":"R25-7-20210214","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2403255","article-title":"Establishment and phenotypic characterization of human U937 cells with inducible P210 BCRABL expression reveals upregulation of CEACAM1 (CD66a).","volume":"3","author":"Hakansson","year":"2004","journal-title":"Leukemia"},{"key":"R26-7-20210214","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.exphem.2003.08.006","article-title":"Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.","volume":"11","author":"Tipping","year":"2003","journal-title":"Exp Hematol"},{"key":"R27-7-20210214","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia.","volume":"8","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"R28-7-20210214","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.leu.2403625","article-title":"Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia.","volume":"3","author":"Gutierrez","year":"2005","journal-title":"Leukemia"},{"key":"R29-7-20210214","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.leukres.2008.07.014","article-title":"Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.","volume":"1","author":"Sanchez-Guijo","year":"2009","journal-title":"Leuk Res"},{"key":"R30-7-20210214","first-page":"1133","article-title":"Imatinib impairs the proliferation and function of CD4CD25 regulatory T cells in a dose-dependent manner.","volume":"5","author":"Chen","year":"2007","journal-title":"Int J Oncol"},{"key":"R31-7-20210214","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1038\/sj.onc.1210179","article-title":"Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.","volume":"28","author":"Nunoda","year":"2007","journal-title":"Oncogene"},{"key":"R32-7-20210214","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/sj.onc.1206603","article-title":"Lats2, a putative tumor suppressor, inhibits G1S transition.","volume":"28","author":"Li","year":"2003","journal-title":"Oncogene"},{"key":"R34-7-20210214","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1074\/jbc.M211562200","article-title":"A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells.","volume":"8","author":"Komatsu","year":"2003","journal-title":"J Biol Chem"},{"key":"R35-7-20210214","doi-asserted-by":"crossref","first-page":"39223","DOI":"10.1074\/jbc.M007291200","article-title":"BCRABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinaseAKT pathway.","volume":"50","author":"Gesbert","year":"2000","journal-title":"J Biol Chem"},{"key":"R36-7-20210214","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","article-title":"New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinaseAKT pathway.","volume":"8","author":"Cantley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R37-7-20210214","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/excr.2000.5130","article-title":"PTEN: life as a tumor suppressor.","volume":"1","author":"Simpson","year":"2001","journal-title":"Exp Cell Res"},{"key":"R38-7-20210214","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/onc.2008.24","article-title":"FOXOs, cancer and regulation of apoptosis.","volume":"16","author":"Fu","year":"2008","journal-title":"Oncogene"},{"key":"R40-7-20210214","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCRABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.","volume":"1","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"R41-7-20210214","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/sj.onc.1206620","article-title":"Chronic myelogenous leukemia molecular signature.","volume":"25","author":"Nowicki","year":"2003","journal-title":"Oncogene"},{"key":"R42-7-20210214","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1097-2765(01)00357-4","article-title":"BCRABL regulates mammalian RecA homologs, resulting in drug resistance.","volume":"4","author":"Slupianek","year":"2001","journal-title":"Mol Cell"},{"key":"R43-7-20210214","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1038\/sj.onc.1206087","article-title":"BCRABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability.","volume":"56","author":"Skorski","year":"2002","journal-title":"Oncogene"},{"key":"R44-7-20210214","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/sj.onc.1207098","article-title":"Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability.","volume":"2","author":"Richardson","year":"2004","journal-title":"Oncogene"},{"key":"R45-7-20210214","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/nar\/29.3.662","article-title":"RAD51 supports spontaneous non-homologous recombination in mammalian cells, but not the corresponding process induced by topoisomerase inhibitors.","volume":"3","author":"Arnaudeau","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"R46-7-20210214","first-page":"7377","article-title":"Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.","volume":"21","author":"Russell","year":"2003","journal-title":"Cancer Res"},{"key":"R47-7-20210214","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1182\/blood-2002-10-3011","article-title":"Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.","volume":"11","author":"Deutsch","year":"2003","journal-title":"Blood"},{"key":"R48-7-20210214","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCRABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.","volume":"12","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"R49-7-20210214","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCRABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.","volume":"32","author":"Sattler","year":"2000","journal-title":"J Biol Chem"},{"key":"R50-7-20210214","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK12 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.","volume":"15","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-201205000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T15:35:07Z","timestamp":1646235307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201205000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e328351f3e9","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}